Programs/ Investments
Primary Indication
Psychedelic Programs & Strategic Investments
COMP3601 / Psilocybin
Treatment-Resistant Depression
BPL-0032 / 5-MEO-DMT
Treatment-Resistant Depression
DMX-1002 / Ibogaine
Opioid Use Disorder
VLS-01 / DMT
Treatment-Resistant Depression
ELE-1012 / Psilocin
Major Depressive Disorder
EMP-01 / R-MDMA
Post-Traumatic Stress Disorder & others
EGX-A & EGX-B / Novel 5-HT2A Receptor Agonists
Undisclosed
Non-Psychedelic Programs
RL-007 / Pro-cognitive neuromodulator3
Cognitive Impairment Associated with Schizophrenia
Phase 2
GRX-917 / Deuterated etifoxine
Generalized Anxiety Disorder
Phase 1
1 Strategic Investment in Compass Pathways
2 Strategic Investment in Beckley PsyTech
3 RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salts
Strategic Investment
JOIN THE ATAI #INSIGHTNETWORK
Receive the latest news on atai and innovations in the space.
Email